2n7f
From Proteopedia
(Difference between revisions)
(New page: '''Unreleased structure''' The entry 2n7f is ON HOLD Authors: Schroeder, C.I., Mobli, M. Description: NMR solution structure of muO-conotoxin MfVIA Category: Unreleased Structures ...) |
|||
| (7 intermediate revisions not shown.) | |||
| Line 1: | Line 1: | ||
| - | '''Unreleased structure''' | ||
| - | + | ==NMR solution structure of muO-conotoxin MfVIA== | |
| + | <StructureSection load='2n7f' size='340' side='right'caption='[[2n7f]]' scene=''> | ||
| + | == Structural highlights == | ||
| + | <table><tr><td colspan='2'>[[2n7f]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Synthetic_construct Synthetic construct]. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2N7F OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=2N7F FirstGlance]. <br> | ||
| + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">Solution NMR, 20 models</td></tr> | ||
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=2n7f FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2n7f OCA], [https://pdbe.org/2n7f PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=2n7f RCSB], [https://www.ebi.ac.uk/pdbsum/2n7f PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=2n7f ProSAT]</span></td></tr> | ||
| + | </table> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | The muO-conotoxins MrVIA, MrVIB and MfVIA inhibit the voltage-gated sodium channel NaV1.8, a well-described target for the treatment of pain; however, little is known about the residues or structural elements that define this activity. In this study, we determined the three-dimensional structure of MfVIA, examined its membrane-binding properties, performed alanine-scanning mutagenesis and identified residues important for its activity at human NaV1.8. A second round of mutations resulted in [E5K,E8K]MfVIA, a double mutant with greater positive surface charge and greater affinity for lipid membranes compared to MfVIA. This analogue had increased potency at NaV1.8 and was analgesic in the mouse formalin assay. | ||
| - | + | Development of a muO-conotoxin Analogue with Improved Lipid Membrane Interactions and Potency for the Analgesic Target NaV1.8.,Deuis JR, Dekan Z, Inserra MC, Lee TH, Aguilar MI, Craik DJ, Lewis RJ, Alewood PF, Mobli M, Schroeder CI, Henriques ST, Vetter I J Biol Chem. 2016 Mar 29. pii: jbc.M116.721662. PMID:27026701<ref>PMID:27026701</ref> | |
| - | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
| - | [[Category: | + | </div> |
| - | [[Category: | + | <div class="pdbe-citations 2n7f" style="background-color:#fffaf0;"></div> |
| - | [[Category: Mobli | + | == References == |
| + | <references/> | ||
| + | __TOC__ | ||
| + | </StructureSection> | ||
| + | [[Category: Large Structures]] | ||
| + | [[Category: Synthetic construct]] | ||
| + | [[Category: Mobli M]] | ||
| + | [[Category: Schroeder CI]] | ||
Current revision
NMR solution structure of muO-conotoxin MfVIA
| |||||||||||
